EMCO-VA
Conditions
Brief summary
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a well-established lifesaving treatment for refractory cardiogenic shock, with or without concomitant respiratory failure. VA-ECMO is usually started in presence of refractory low cardiac output syndrome following CPB weaning. Currently, there is no consensus about the best timing for implantation and initiation of VA-ECMO in this setting. Some publications have suggested that VIS score could be used to determine the necessity of VA-ECMO in cardiologic area. It was demonstrated that a VIS score between 20 and 40 may be a cut-off value to discuss the implantation of VA-ECMO. Post cardiotomy shock is a very interesting setting because the timing of cardiogenic shock is known and several bias are more controlled than in medical area. Based on the well-established ability of VIS Score in predicting mortality, we will investigate the role of the VIS Score as a determinant for early VA-ECMO implantation in patients suffering of post-cardiotomy cardiogenic shock.
Interventions
OTHERdata collection
age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age over 18 years * Cardiac surgery with cardiopulmonary bypass * Post cardiotomy cardiogenic shock * ECMO-VA implanted in OR
Exclusion criteria
* LVAD * Heart transplantation * Incomplete data in relation to outcomes * Cardiac arrest
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pourcentage of death | Day 30 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1 - Number of complications | Day 30 | 1- cardiac, neurological, renal, respiratory, red blood transfusion complication |
| 2 - number of days in intensive care | through study completion, up to 15 days | — |
| 3 - number of days in hospital | through study completion, up to 3 months | — |
Countries
France
Outcome results
None listed